Sub-clinical hypothyroidism interferes with growth hormone therapy

[yzfrr11]

Consider running T4 or Armour with your HGH bros -

Growth hormone/insulin-like growth factor axis in patients with subclinical thyroid dysfunction.
Akin F, Yaylali GF, Turgut S, Kaptanoglu B.
Source

University of Pamukkale, Faculty of Medicine, Department of Endocrinology and Metabolism, Denizli, Turkey. [email protected]
Abstract
OBJECTIVE:

Our aim was to evaluate serum concentrations of GH, IGF-I, and insulin-like growth factor-binding protein-3 (IGFBP-3) in patients with subclinical thyroid dysfunction before and after normalization of thyroid function.
DESIGN AND METHODS:

The study included 51 patients (mean age 42.2+/-1.8 years) with subclinical hypothyroidism and 30 patients (mean age 44.3+/-2.4 years) with subclinical hyperthyroidism. A group of 37 euthyroid healthy subjects were studied as controls. Serum concentrations of TSH, FT4, FT3, GH, insulin, IGF-I, and IGFBP-3 were measured in all patients before starting therapy and after normalization of thyroid function. The dosage of levothyroxine (LT4) and antithyroid drugs was adjusted in attempt to keep the serum-free thyroxine (FT4) and thyrotropin (TSH) concentrations within the normal range.
MAIN OUTCOME:

Baseline growth hormone levels were similar with hypothyroid group and hyperthyroid group in relation to euthyroid control subjects. Fasting serum IGF-I levels were significantly lower in the subclinical hypothyroid group compared with the control group. On the other hand, IGF-I levels of subclinical hyperthyroid patients and control group were similar. After normalization of thyroid function tests, IGF-I concentrations were increased in subclinical hypothyroid subjects, but unchanged in subclinical hyperthyroid subjects. Patients with subclinical hyperthyroidism showed slightly lower mean serum IGFBP-3 concentrations than those found in control group, but the difference was not statistically significant. Serum GH and IGFBP-3 levels were unaltered by treatment.
CONCLUSIONS:

In this study, it was shown that GH-IGF axis was not affected in patients with subclinical hyperthyroidism, while it was affected in patients with subclinical hypothyroidism. That is, investigation of the axis in subclinical hyperthyroidism would not bring any extra advantages, but LT4 replacement therapy could prevent abnormalities related to GH-IGF axis in patients with subclinical hypothyroidism.

 

[Performance Based]

what dosage is recommended (pardon me if I did not see it in the thread). Also taken 1x or 2x per day?

This is something I just started reading about.

 

[yzfrr11]

Use T4, not T3 for thyroid support bros -

Relationships between the thyroid and somatotropic axes in steers. II: Effects of thyroid status on plasma concentrations of insulin-like growth factor I (IGF-I) and the IGF-I response to growth hormone.
Elsasser TH, Rumsey TS, Kahl S.
Source

U.S. Department of Agriculture, Ruminant Nutrition Laboratory, Beltsville, MD 20705.
Abstract

Three studies assessed the effect of thyroid status on regulation of plasma IGF-I in cattle. First, four Angus-Hereford steers (av wt 345 kg) were fed 4 mg/d propylthiouracil daily for 35 d. With continued feeding of PTU steers were sequentially injected with thyroxine (T4, 5 mg/d, IM for 5 d) followed by triiodothyronine (T3, 2 mg/d, IM for 5 d). An injection of bovine pituitary growth hormone (GH, 0.1 mg/kg, IM) was given to each steer on day 35 of PTU, day 5 of T4 and again on day 5 of T3. PTU alone increased plasma thyroid stimulating hormone (TSH), decreased plasma T4 and T3 but had no influence on IGF-I. T3, but not T4, lowered plasma TSH, IGF-I and the IGF-I response to GH (P < .05). Next, twelve bull calves (av wht 167 kg) were divided equally into two groups. A control group was injected daily for five d with buffered saline; the experimental group was concurrently treated with T3 (5 mg/d, sc) for five d. Beginning the sixth day, all calves were injected with GH (0.1 mg/kg, IM daily) for three d with the respective buffer or T3 treatments continuing. Plasma IGF-I was depressed 29% by T3. The incremental area under the three-d response curve was less (P < .03) in T3 cattle. A growth trial was conducted in which twenty-four Angus x Hereford steers were injected daily with T3 (2 mg/kg, bi-daily x 56 d) or implanted with Synovex-S (S) in a 2 x 2 factorial arrangement. Synovex increased empty body protein gain (EBPG) and plasma IGF-I 15.5 and 27.9% (P < .01), respectively; T3 decreased EBPG and plasma IGF-I 13.9 and 15.1% (P < .07), respectively, in steers which maintained suppression in plasma TSH. The data support the conclusion that elevated T3 decreases plasma IGF-I, in part, through a diminished GH-responsiveness and anabolic treatments such as S can reverse the effects of excess T3.